EDITEditas Medicine, Inc.

EDIT Stock Price, Valuation & Chart | Editas Medicine, Inc.

Compare

$3.080+0.01 (+0.33%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology EDIT intrinsic value EDIT calculated fair value vs price

Overview Financials Dividends Ratios

EDIT Historical price chart

EDIT Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization472.66M

PE Ratio-4.11

EPS-0.75

Trading Volume1.67M

Today's High/Low3.23/2.98

Dividend Yield0.00

52 Week High/Low4.54/1.66

Shares Outstanding153.46M

EDIT Financial Statement

EDIT Analyst ratings

EDIT Analysis & performance metrics

EDIT Company profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a…

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also…

EDIT Management team

Name

Position

Gregory Whitehead

Executive Vice President and Chief Technical & Quality Officer

Cristi Barnett

Senior Vice President of Corporate Communications & Investor Relations

Frank Panaccio

Senior Vice President & Chief Business Officer

George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Gilmore O'Neill M.D.CEO

President, Chief Executive Officer & Director

Amy ParisonCFO

Senior Vice President & Chief Financial Officer

Linea Aspesi

Executive Vice President & Chief Administration Officer

Linda C. Burkly Ph.D.

Executive Vice President & Chief Scientific Officer

Name

Position

Gregory Whitehead

Executive Vice President and Chief Technical & Quality Officer

Cristi Barnett

Senior Vice President of Corporate Communications & Investor Relations

Frank Panaccio

Senior Vice President & Chief Business Officer

George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Gilmore O'Neill M.D.CEO

President, Chief Executive Officer & Director

Amy ParisonCFO

Senior Vice President & Chief Financial Officer

Linea Aspesi

Executive Vice President & Chief Administration Officer

Linda C. Burkly Ph.D.

Executive Vice President & Chief Scientific Officer

Management Team

Gregory Whitehead

Executive Vice President and Chief Technical & Quality Officer

Cristi Barnett

Senior Vice President of Corporate Communications & Investor Relations

Frank Panaccio

Senior Vice President & Chief Business Officer

George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Gilmore O'Neill M.D.CEO

President, Chief Executive Officer & Director

Amy ParisonCFO

Senior Vice President & Chief Financial Officer

Linea Aspesi

Executive Vice President & Chief Administration Officer

Linda C. Burkly Ph.D.

Executive Vice President & Chief Scientific Officer

Management

Gregory Whitehead

Executive Vice President and Chief Technical & Quality Officer

Cristi Barnett

Senior Vice President of Corporate Communications & Investor Relations

Frank Panaccio

Senior Vice President & Chief Business Officer

George McDonald Church Ph.D.

Co-Founder & Scientific Advisory Board Member

Gilmore O'Neill M.D.CEO

President, Chief Executive Officer & Director

Amy ParisonCFO

Senior Vice President & Chief Financial Officer

Linea Aspesi

Executive Vice President & Chief Administration Officer

Linda C. Burkly Ph.D.

Executive Vice President & Chief Scientific Officer

Total 8 executives

EDIT Frequently asked questions

What is Editas Medicine, Inc. (EDIT) Stock Price?

Current stock price of Editas Medicine, Inc. (EDIT) stock is $3.080. The stock price is +0.33% higher in the session. The intraday range can be seen from this page. Volume of Editas Medicine, Inc. (EDIT) stock is 1.67M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Editas Medicine, Inc. (EDIT) stock price going up or down today?

The stock price of Editas Medicine, Inc. (EDIT) can change with earnings, company news, and overall market sentiment. Editas Medicine, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Editas Medicine, Inc. stock expensive at its current price?

Whether Editas Medicine, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for EDIT on this page is -4.11. EPS on this page is -0.75. Compare those figures with peers and growth expectations before deciding if the current Editas Medicine, Inc. price is justified.

How has the stock price of Editas Medicine, Inc. (EDIT) performed historically?

Historical performance for Editas Medicine, Inc. (EDIT) is shown on the price chart on this page. Review multi-period moves alongside volume to see how EDIT reacted to past earnings and market events.

Should I buy Editas Medicine, Inc. (EDIT) stock, at this price?

Buying Editas Medicine, Inc. (EDIT) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.